Antigen forks : bispecific reagents that inhibit cell growth by binding selected pairs of tumor antigens

• Published in: Cancer Immunology Immunotherapy Vol. 39; no. 1; pp. 41 - 48
• Main Authors: RING, D. B, HSIEH-MA, S. T, SHI, T, REEDER, J
• Format: Journal Article
• Language: English
• Published: Berlin Springer 01.01.1994; Springer-Verlag
• Subjects: Animals; Antibodies, Bispecific - immunology; Antibodies, Bispecific - metabolism; Antibodies, Bispecific - pharmacology; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - metabolism; Antibodies, Monoclonal - pharmacology; Antigen-Antibody Reactions; Antigens, Neoplasm - immunology; Antigens, Neoplasm - metabolism; Antigens, Neoplasm - pharmacology; Antineoplastic agents; Biological and medical sciences; Cell Division - drug effects; Chromatography, High Pressure Liquid; Cross-Linking Reagents - chemistry; Humans; Immunotherapy; Immunotoxins - immunology; Immunotoxins - metabolism; Immunotoxins - pharmacology; Medical sciences; Mice; Original; Pharmacology. Drug treatments; Succinimides - chemistry; Antineoplastic agent; Human; Cell proliferation; Tumor associated antigen; Crosslinking; Monoclonal antibody; Bispecific antibody; In vitro; Biological fixation; Preparation; Established cell line; Covalent bond; Dimer; Coupling; Inhibition; Conjugated compound; Tumor cell
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/BF01517179

Bispecific antibodies of a new category, termed "antigen forks", were constructed by crosslinking antibodies that recognized pairs of distinct tumor cell surface antigens. At concentrations of 1-100 nM, several such forks inhibited the growth of human tumor cell lines bearing both relevant antigens. The same cells were not inhibited by unconjugated component antibodies, and the active conjugates did not inhibit the growth of human cell lines that expressed lower levels of relevant antigens. The three most active antigen forks all contained monoclonal antibody 454A12, which recognizes human transferrin receptor. This antibody was conjugated respectively to antibodies 113F1 (against a tumor-associated glycoprotein complex), 317G5 (against a 42-kDa tumor-associated glycoprotein), or 520C9 (against the c-erbB-2 protooncogene product). The 317G5-454A12 fork strongly inhibited the HT-29 and SW948 human colorectal cancer cell lines, while the 113F1-454A12 and 520C9-454A12 forks strongly inhibited the SK-BR-3 human breast cancer cell line and the 113F1-454A12 fork was also effective against SW948. By designing forks against antigens of incompatible function that are co-expressed at high levels on tumor cells but not on normal tissues, it may be possible to generate reagents that inhibit tumor growth with enhanced selectivity.